Celldex Therapeutics Shares Outstanding 2010-2022 | CLDX
Celldex Therapeutics shares outstanding from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Celldex Therapeutics Annual Shares Outstanding
(Millions of Shares) |
| 2021 |
43 |
| 2020 |
30 |
| 2019 |
15 |
| 2018 |
10 |
| 2017 |
9 |
| 2016 |
7 |
| 2015 |
6 |
| 2014 |
6 |
| 2013 |
5 |
| 2012 |
4 |
| 2011 |
3 |
| 2010 |
2 |
| 2009 |
1 |
Celldex Therapeutics Quarterly Shares Outstanding
(Millions of Shares) |
| 2022-09-30 |
47 |
| 2022-06-30 |
47 |
| 2022-03-31 |
47 |
| 2021-12-31 |
43 |
| 2021-09-30 |
45 |
| 2021-06-30 |
40 |
| 2021-03-31 |
40 |
| 2020-12-31 |
30 |
| 2020-09-30 |
39 |
| 2020-06-30 |
22 |
| 2020-03-31 |
17 |
| 2019-12-31 |
15 |
| 2019-09-30 |
15 |
| 2019-06-30 |
14 |
| 2019-03-31 |
12 |
| 2018-12-31 |
10 |
| 2018-09-30 |
11 |
| 2018-06-30 |
10 |
| 2018-03-31 |
9 |
| 2017-12-31 |
9 |
| 2017-09-30 |
9 |
| 2017-06-30 |
8 |
| 2017-03-31 |
8 |
| 2016-12-31 |
7 |
| 2016-09-30 |
7 |
| 2016-06-30 |
7 |
| 2016-03-31 |
7 |
| 2015-12-31 |
6 |
| 2015-09-30 |
7 |
| 2015-06-30 |
7 |
| 2015-03-31 |
6 |
| 2014-12-31 |
6 |
| 2014-09-30 |
6 |
| 2014-06-30 |
6 |
| 2014-03-31 |
6 |
| 2013-12-31 |
5 |
| 2013-09-30 |
5 |
| 2013-06-30 |
5 |
| 2013-03-31 |
5 |
| 2012-12-31 |
4 |
| 2012-09-30 |
4 |
| 2012-06-30 |
4 |
| 2012-03-31 |
3 |
| 2011-12-31 |
3 |
| 2011-09-30 |
3 |
| 2011-06-30 |
2 |
| 2011-03-31 |
2 |
| 2010-12-31 |
2 |
| 2010-09-30 |
2 |
| 2010-06-30 |
2 |
| 2010-03-31 |
2 |
| 2009-12-31 |
1 |
| 2009-09-30 |
1 |
| 2009-06-30 |
1 |
| 2009-03-31 |
1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.080B |
$0.005B |
|
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
|
